

Editorial

*Corresponding author

Guilherme H. Oliveira, MD, FACC

Associate Professor of Medicine
Chief, Heart Failure Section
Director, Onco-Cardiology Program
Seidman Cancer Center
Director, Advanced Heart Failure and
Transplantation Center
Harrington Heart and Vascular Institute
Case Western Reserve University School
of Medicine
University Hospitals Case Medical Center
11100 Euclid Ave. Cleveland
OH 44106, USA

E-mail: guilherme.oliveira@uhhospitals.org

Volume 2 : Issue 4

Article Ref. #: 1000HROJ2e004

Article History

Received: November 15th, 2015

Accepted: November 16th, 2015

Published: November 16th, 2015

Citation

Kim CH, Al-Kindi S, Oliveira GH. Anthracycline cardiotoxicity: strategies for prevention and intervention. *Heart Res Open J.* 2015; 2(4): e9-e12. doi: [10.17140/HROJ-2-e004](https://doi.org/10.17140/HROJ-2-e004)

Copyright

©2015 Oliveira GH. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Anthracycline Cardiotoxicity: Strategies for Prevention and Intervention

Chang H. Kim^{1,2}, Sadeer Al-Kindi^{1,2} and Guilherme H. Oliveira^{1,2,3*}

¹Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH, USA

²School of Medicine, Case Western Reserve University, Cleveland, OH, USA

³Harrington Heart and Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH, USA

KEYWORDS: Anthracycline cardiotoxicity; Echocardiography; Strain imaging; Global longitudinal strain.

The cardiotoxic effects of anthracycline compounds, used extensively to treat malignancies such as breast cancer and lymphoma, are well known.^{1,2} However, despite efforts towards cardioprotective strategies and early detection of anthracycline cardiotoxicity, defined as decline in Left Ventricular Ejection Fraction (LVEF) of $\geq 10\%$ from baseline or to $< 50\%$,^{3,4} there is currently no consensus on the optimal approach. Current clinical practice guidelines recommend serial LVEF monitoring to identify cardiotoxicity in high-risk patients receiving anthracyclines;^{3,4} however, it has come to light that LVEF reduction may be a late manifestation of cardiotoxicity,^{5,6} with potentially limited prospects for reversibility.⁷⁻⁹ Recently, echocardiographic strain imaging has emerged as a promising way to detect subclinical cardiotoxicity prior to LVEF reduction,¹⁰⁻¹³ where small reduction in Global Longitudinal Strain (GLS) has been identified as a robust predictor of future LVEF reduction and cardiac events.¹⁴⁻¹⁶ The reliability of this approach in patients treated with anthracyclines has been specifically evaluated,¹⁷⁻¹⁹ with reported cardiotoxicity rates ranging from $< 1\%$ to 32% .²⁰ Recent studies have established a GLS reduction of $\geq 11\%$ as a strong predictor of cardiotoxicity.^{19,21-24}

Strategies to mitigate anthracycline cardiotoxicity may be classified as pre-emptive (primary prevention) *versus* reactive (secondary prevention).² For primary prevention, conventional treatments for heart failure, including beta-blockers and angiotensin antagonists, have been evaluated, with promising results in recent meta-analyses.^{25,26} In the recently completed PRADA study, a randomized controlled trial comparing primary prevention of cardiotoxicity with metoprolol, candesartan, *versus* matched placebos in 120 patients treated with anthracyclines with or without trastuzumab for early breast cancer,^{27,28} pre-emptive candesartan was shown to result in a statistically significant attenuation in LVEF decline. In contrast, no similar effect was found with metoprolol succinate use. Additional trials and longer follow-up period are needed to confirm these findings.

Because a primary prevention strategy may needlessly expose many patients to potential adverse effects, secondary prevention strategies are of interest. The implicit assumption of such a strategy is that high risk patients would be detected early enough to be able to initiate treatment while cardiotoxicity is still reversible. In addition to echocardiographic strain, cardiac biomarkers, such as troponin and NT-proBNP, have been evaluated for this purpose. In particular, the degree and duration of troponin elevation was shown to be closely correlated with left ventricular dysfunction^{29,30} and in one randomized controlled trial, initiation of enalapril in patients with early troponin leak following chemotherapy was shown to be associated with significant improvement in LVEF at 1 year follow up.³¹ However, troponin elevation is not always present even in the setting of echocardiographic findings consistent with cardiotoxicity,³²⁻³⁵ and thus, echocardiographic strain imaging may be a more reliable indicator for secondary prevention.

In a recent prospective observational study involving a secondary cardioprotective strategy based on strain imaging,²¹ Negishi, et al. evaluated changes in strain parameters in patients undergoing treatment with anthracyclines and/or trastuzumab, where those showing $\geq 11\%$ drop in GLS at 6 months were followed for an additional 6 months with or without initiation of beta blocker therapy. In the treatment group, GLS and LVEF were significantly improved at 12 months, with significant association with beta-blocker therapy in multivariable analysis. While preliminary in nature, this study is significant for being the first to utilize strain imaging in guiding initiation of cardioprotective therapy.

In conclusion, both primary and secondary cardioprotective strategies with beta-blockers and angiotensin antagonist therapy for anthracycline cardiotoxicity hold promise at this time. In adopting a secondary prevention strategy, GLS measured by echocardiographic strain imaging may be a useful and reliable indicator for timing of intervention. Additional randomized controlled trials with long term follow-up are needed in order to determine the best strategies for prevention of anthracycline cardiotoxicity.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

No funding was received for this manuscript.

REFERENCES

1. Al-Kindi S, Younes A, Qattan M, Oliveira GH. Preemptive cardioprotective strategies in patients receiving chemotherapy. *Curr Cardiovasc Risk Rep.* 2014; 8: 406. doi: [10.1007/s12170-014-0406-5](https://doi.org/10.1007/s12170-014-0406-5)
2. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. *J Am Coll Cardiol.* 2014; 64(9): 938-945. doi: [10.1016/j.jacc.2014.06.1167](https://doi.org/10.1016/j.jacc.2014.06.1167)
3. Hensley ML, Hagerty KL, Kewalramani T, et al. American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. *J Clin Oncol Off J Am Soc Clin Oncol.* 2009; 27(1): 127-145. doi: [10.1200/JCO.2008.17.2627](https://doi.org/10.1200/JCO.2008.17.2627)
4. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. *Ann Oncol.* 2012; 23(Suppl 7): 7155-7166. doi: [10.1093/annonc/mds293](https://doi.org/10.1093/annonc/mds293)
5. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. *Ann Oncol.* 2002; 13:699-709. doi: [10.1093/annonc/mdf132](https://doi.org/10.1093/annonc/mdf132)
6. Manisty CH, Francis DP. Ejection fraction: a measure of desperation? *Heart.* 2008; 94: 400-401. doi: [10.1136/hrt.2007.118976](https://doi.org/10.1136/hrt.2007.118976)
7. Oliveira GH, Mukerji S, Hernandez AV, et al. Incidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patients. *Am J Cardiol.* 2014; 113(11): 1893-1898. doi: [10.1016/j.amjcard.2014.03.018](https://doi.org/10.1016/j.amjcard.2014.03.018)
8. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol.* 2010; 55: 213-220. doi: [10.1016/j.jacc.2009.03.095](https://doi.org/10.1016/j.jacc.2009.03.095)
9. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. *J Clin Oncol.* 2007; 25: 3525-3533. doi: [10.1200/JCO.2007.11.0106](https://doi.org/10.1200/JCO.2007.11.0106)
10. Abraham TP, Dimaano VL, Liang HY. Role of tissue doppler and strain echocardiography in current clinical practice. *Circulation.* 2007; 116(22): 2597-2609. doi: [10.1161/CIRCULATIONAHA.106.647172](https://doi.org/10.1161/CIRCULATIONAHA.106.647172)
11. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. *Am J Cardiol.* 2011; 107: 1375-1380.

12. Stoodley PW, Richards DA, Hui R, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. *Eur Heart J Cardiovasc Imaging*. 2013; 14: 228-334. doi: [10.1093/ehjci/jes139](https://doi.org/10.1093/ehjci/jes139)
13. Tsai HR, Gjesdal O, Wethal T, et al. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. *Am J Cardiol*. 2011; 107: 472-477. doi: [10.1016/j.amjcard.2010.09.048](https://doi.org/10.1016/j.amjcard.2010.09.048)
14. Mele D, Rizzo P, Pollina AV, Fiorencis A, Ferrari R. Cancer therapy-induced cardiotoxicity: role of ultrasound deformation imaging as an aid to early diagnosis. *Ultrasound Med Biol*. 2014; 41(3): 627-641. doi: [10.1016/j.ultrasmedbio.2014.11.015](https://doi.org/10.1016/j.ultrasmedbio.2014.11.015)
15. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. *Heart*. 2014; 100: 1673-1680. doi: [10.1136/heartjnl-2014-305538](https://doi.org/10.1136/heartjnl-2014-305538)
16. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. *J Am Soc Echocardiogr*. 2013; 26: 493-498. doi: [10.1016/j.echo.2013.02.008](https://doi.org/10.1016/j.echo.2013.02.008)
17. Mavinkurve-Groothuis AM, Marcus KA, Pourier M, et al. Myocardial 2-D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. *Eur Heart J Cardiovasc Imaging*. 2013; 14: 562-569. doi: [10.1093/ehjci/jes217](https://doi.org/10.1093/ehjci/jes217)
18. Kang Y, Cheng L, Li L, et al. Early detection of anthracycline-induced cardiotoxicity using two dimensional speckle tracking echocardiography. *Cardiol J*. 2013; 20: 592-599. doi: [10.5603/CJ.2013.0158](https://doi.org/10.5603/CJ.2013.0158)
19. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. *Circ Cardiovasc Imaging*. 2012; 5: 596-603. doi: [10.1161/CIRCIMAGING.112.973321](https://doi.org/10.1161/CIRCIMAGING.112.973321)
20. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy-a systematic review. *J Am Coll Cardiol*. 2014; 63(25): 2751-2768. doi: [10.1016/j.jacc.2014.01.073](https://doi.org/10.1016/j.jacc.2014.01.073)
21. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. *Eur Heart J Cardiovasc Imaging*. 2014; 15: 324-331. doi: [10.1093/ehjci/jet159](https://doi.org/10.1093/ehjci/jet159)
22. Baratta S, Damiano M, Marchese M, et al. Serum markers, conventional doppler echocardiography and two-dimensional systolic strain in the diagnosis of chemotherapy-induced myocardial toxicity. *Rev Argent Cardiol*. 2013; 81: 151-158.
23. Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. *Can J Physiol Pharmacol*. 2013; 91: 601-607. doi: [10.1139/cjpp-2012-0398](https://doi.org/10.1139/cjpp-2012-0398)
24. Fallah-Rad N, Walker JR, Wassef A, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. *J Am Coll Cardiol*. 2011; 57: 2263-2270. doi: [10.1016/j.jacc.2010.11.063](https://doi.org/10.1016/j.jacc.2010.11.063)
25. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. *Eur J Cancer*. 2013; 49: 2900-2909. doi: [10.1016/j.ejca.2013.04.030](https://doi.org/10.1016/j.ejca.2013.04.030)
26. Yun S, Vincelette ND, Abraham I. Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. *Postgrad Med J*. 2015; 91(1081): 627-633. doi: [10.1136/postgradmedj-2015-133535](https://doi.org/10.1136/postgradmedj-2015-133535)
27. Heck SL, Gulati G, Ree AH, et al. Rational and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial. *Cardiology*. 2012; 123(3): 240-247. doi: [10.1159/000343622](https://doi.org/10.1159/000343622)

28. Gulati G, Heck SL, Ree HR, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): primary results of a randomized, 2x2 factorial, placebo-controlled, double-blind clinical trial. www.clinicaltrialresults.org/Slides/AHA2015/Gulati_PRADA.ppt
29. Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. *Ann Hematol.* 2003; 82(4): 218-222. doi: [10.1007/s00277-003-0615-3](https://doi.org/10.1007/s00277-003-0615-3)
30. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. *J Am Coll Cardiol.* 2000; 36(2): 517-522. doi: [10.1016/S0735-1097\(00\)00748-8](https://doi.org/10.1016/S0735-1097(00)00748-8)
31. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin converting enzyme inhibition. *Circulation.* 2006; 114: 2474-2481. doi: [10.1161/CIRCULATIONAHA.106.635144](https://doi.org/10.1161/CIRCULATIONAHA.106.635144)
32. Koseoglu V, Berberoglu S, Karademir S, et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin? *Turk J Pediatr.* 2005; 47(1): 17-22.
33. Mathew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? a pilot study. *Cancer Investig.* 2001; 19(4): 352-359. doi: [10.1081/CNV-100103130](https://doi.org/10.1081/CNV-100103130)
34. Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. *Clin Cancer Res Off J Am Assoc Cancer Res.* 2011; 17(10): 3490-3499. doi: [10.1158/1078-0432.CCR-10-1359](https://doi.org/10.1158/1078-0432.CCR-10-1359)
35. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies. *J Am Coll Cardiol.* 2013; 61(23): 2355-2362. doi: [10.1016/j.jacc.2013.02.072](https://doi.org/10.1016/j.jacc.2013.02.072)